Effectiveness of Spironolactone in Reducing Osteoporosis and Future Fracture Risk in Middle-Aged and Elderly Hypertensive Patients.
Shuaiwei SongXin-Tian CaiJunli HuQing ZhuDi ShenHuimin MaYingying ZhangRui MaWenbo YangJing HongDelian ZhangNanfang LiPublished in: Drug design, development and therapy (2024)
This study offers evidence supporting the significant positive impact of the antihypertensive drug spironolactone on bone health, resulting in a substantial reduction in the risk of osteoporosis and future fractures in hypertensive patients. Future research should consider conducting large-scale, multicenter, randomized controlled trials to further investigate the long-term effects of spironolactone on bone health in hypertensive patients.
Keyphrases
- hypertensive patients
- blood pressure
- bone mineral density
- current status
- postmenopausal women
- randomized controlled trial
- public health
- healthcare
- mental health
- health information
- systematic review
- body composition
- bone loss
- middle aged
- bone regeneration
- emergency department
- cross sectional
- community dwelling
- electronic health record